Teva UK Limited Launches Latanoprost + Timolol Eye Drops

CASTLEFORD, England, February 8, 2012 /PRNewswire/ --

We are pleased to announce the launch of Latanoprost + Timolol 0.05mg/ml + 5mg/ml Eye Drops.

It is indicated in the treatment of the reduction of elevated intraocular pressure in patients with open angle glaucoma and ocular hypertension.  Latanoprost + Timolol is now available from Teva to fulfil generic prescriptions.

Latanoprost + Timolol is currently available as Xalacom^® (Latanoprost + Timolol) from Pfizer Limited and is available immediately in the award-winning Teva 360 livery. The strength and presentation is as follows:

                                                                                  Teva
                                                                                 retail     Brand
                Product      Strength        Pack Size       Indication          price      price
            
                Latanoprost   0.05mg/ml    2.5ml x 1   Reduction of elevated    GBP12.17   GBP14.32
                + Timolol      + 5mg/ml                intraocular pressure in
                Eye Drops                                patients with open
                                                         angle glaucoma and
                                                         ocular hypertension   
            

Kim Innes, Commercial Director at Teva said: "As the leading generics company in the country and with the widest portfolio of our competitors, Teva continues with strong product launches.   This is our second new product launch for this year".

New or existing customers can order through their local Teva Territory Sales Manager, by completing the online form, or calling on 0800 085 8621.

To find out more about Teva UK Limited, visit http://www.tevauk.com.

*Brand price at 7 February 2012

Notes to Editors:

About Teva UK Limited

Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers, with a presence in the generics, branded respiratory and hospitals markets. It has the widest range of any UK generic pharmaceutical company and markets solid and liquid dose, injectable and respiratory medicines to healthcare professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 47,000 people around the world and reached $16.1 billion in net sales in 2010.

For media enquiries, contact the Teva UK Limited Media team on +44(0)1977-628500, or email media.enquiries@tevauk.com.